SGLT2 inhibitors have shown salutary cardiovascular and renal benefits in patients with T2D and signified a new era, in which antidiabetic therapies should be based on end-organ protection and patient comorbidities, rather than aiming only on decreasing blood glucose concentration [8891]
Your healthcare provider will prescribe an appropriate starting dose and provide guidelines on when and how to increase the dosage
Humanin, initially discovered for its role in neuroprotection, has since garnered interest for its broad spectrum of cytoprotective effects
Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al
Unfortunately, most are given little guidance, risking issues like malnutrition, muscle loss, and fatigue as they lose weight
Novo Nordisk launched the product in the United States in January 2026, marking the first time an oral GLP-1 treatment had been cleared specifically for weight management